Tirzepatide Injection

[Indications]
It is suitable for the treatment of type 2 diabetes mellitus in adults as an adjunct to diet and exercise to improve glycemic control. It is also indicated for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition, in combination with a reduced-calorie diet and increased physical activity.

[Usage and dosage]
This product is administered by subcutaneous injection once weekly. The recommended starting dose is 2.5 mg once weekly for 4 weeks. After 4 weeks, the dose should be increased to 5 mg once weekly. If additional glycemic control or weight reduction is required, the dose may be increased in 2.5 mg increments after at least 4 weeks on the current dose. The maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. The maximum recommended dose is 15 mg once weekly. The injection should be administered in the abdomen, thigh, or upper arm, and the injection site should be rotated.